Literature DB >> 24026910

Problems and solutions in laboratory testing for hemophilia.

Emmanuel J Favaloro1, Piet Meijer, Ian Jennings, John Sioufi, Roslyn A Bonar, Dianne P Kitchen, Geoffrey Kershaw, Giuseppe Lippi.   

Abstract

A diagnosis of hemophilia A or hemophilia B begins with clinical assessment of the patient and is facilitated by laboratory testing. The influence of the latter on a diagnosis of hemophilia A or hemophilia B is clear-a diagnosis cannot be made without laboratory confirmation of a deficiency of factor FVIII (FVIII) or factor IX (FIX), respectively. Moreover, the degree of hemophilia severity is specifically characterized by laboratory test results. In turn, patient management, including choice and application of therapies, is influenced by the diagnosis, as well as by identification of respective disease severity. An incorrect diagnosis may lead to inappropriate management and unnecessary therapy, and thus to adverse outcomes. Moreover, identification of factor inhibitors in hemophilia will lead to additional and differential treatments, and incorrect identification of inhibitors or inhibitor levels may also lead to inappropriate management. Problems in hemophilia diagnosis or inhibitor detection can occur at any stage in the clinical diagnosis/laboratory interface, from the "pre-preanalytical" to "preanalytical" to "analytical" to "postanalytical" to "post-postanalytical." This report outlines the various problems in laboratory testing for hemophilia and provides various strategies or solutions to overcome these challenges. Although some outlined solutions are specific to the potential errors related to hemophilia, others are general in nature and can be applied to other areas of laboratory hemostasis. Key to improvement in this area is adoption of best practice by all involved, including clinicians, phlebotomists, and laboratories. Also key is the recognition that such errors may occur, and thus that clinicians should assess laboratory test results in the context of their patient's clinical history and follow-up any potential errors, thus avoid misdiagnoses, by requesting repeat testing on a fresh sample. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Year:  2013        PMID: 24026910     DOI: 10.1055/s-0033-1356573

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  5 in total

1.  Emerging treatments for hemophilia: patients and their treaters spoilt for choice, but laboratories face a difficult path?

Authors:  Emmanuel J Favaloro; Giuseppe Lippi
Journal:  Ann Transl Med       Date:  2017-03

2.  Limit of detection and threshold for positivity of the Centers for Disease Control and Prevention assay for factor VIII inhibitors.

Authors:  C H Miller; B Boylan; A D Shapiro; S R Lentz; B M Wicklund
Journal:  J Thromb Haemost       Date:  2017-09-14       Impact factor: 5.824

3.  Monitoring standard and extended half-life products in hemophilia: Assay discrepancies for factor VIII and IX in pre- and postinfusion samples.

Authors:  Cecilia Augustsson; Eva Norström; Nadine Gretenkort Andersson; Eva Zetterberg; Jan Astermark; Karin Strandberg
Journal:  Res Pract Thromb Haemost       Date:  2020-08-11

4.  Estimation of Nuwiq® (simoctocog alfa) activity using one-stage and chromogenic assays-Results from an international comparative field study.

Authors:  Stefan Tiefenbacher; Manuela Albisetti; Peter Baker; Guenther Kappert; Steve Kitchen; Johanna A Kremer Hovinga; Claire Pouplard; Ute Scholz; Catherine Ternisien; Carin Borgvall; Tiago Vicente; Larisa Belyanskaya; Olaf Walter; Johannes Oldenburg
Journal:  Haemophilia       Date:  2019-05-20       Impact factor: 4.287

5.  Analytical variation in factor VIII one-stage and chromogenic assays: Experiences from the ECAT external quality assessment programme.

Authors:  Iris van Moort; Piet Meijer; Debby Priem-Visser; Adriaan J van Gammeren; Nathalie C V Péquériaux; Frank W G Leebeek; Marjon H Cnossen; Moniek P M de Maat
Journal:  Haemophilia       Date:  2018-11-29       Impact factor: 4.287

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.